Completed PHASE4 INTERVENTIONAL NCT00502775

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis

Sponsor: GlaxoSmithKline

Interventions fluticasone furoate, fexofenadine

Updated 7 times since 2017 Last updated: Oct 27, 2016 Started: Aug 31, 2007 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00502775, this PHASE4 trial focuses on Rhinitis, Allergic, Seasonal and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Canton, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Columbia, United States , Columbus, United States , Evansville, United States , Greenfield, United States , Indianapolis, United States and 30 more locations